These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2653922)

  • 21. Pharmacological replacement of cholinergic function in Alzheimer disease.
    Giacobini E
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():412A-413A. PubMed ID: 1498895
    [No Abstract]   [Full Text] [Related]  

  • 22. Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease.
    Davis R; Raby C; Callahan MJ; Lipinski W; Schwarz R; Dudley DT; Lauffer D; Reece P; Jaen J; Tecle H
    Prog Brain Res; 1993; 98():439-45. PubMed ID: 8248534
    [No Abstract]   [Full Text] [Related]  

  • 23. [Alzheimer's disease. Biological and pharmacotherapeutic aspects].
    Hinzen DH
    Fortschr Med; 1986 Jun; 104(23-24):469-71. PubMed ID: 3017825
    [No Abstract]   [Full Text] [Related]  

  • 24. Strategies for the pharmacological treatment of Alzheimer's disease.
    Brinkman SD; Largen JW
    Tex Med; 1987 Jan; 83(1):26-30. PubMed ID: 3824229
    [No Abstract]   [Full Text] [Related]  

  • 25. Cholinergic drug infusion and Alzheimer's disease.
    Roberts DW; Coombs DW; Saunders RL; Reeder TM
    Neurosurgery; 1985 Apr; 16(4):584. PubMed ID: 3990941
    [No Abstract]   [Full Text] [Related]  

  • 26. Combination therapy with galantamine and memantine improves behavioral and psychological symptoms of dementia (BPSD) in patients with early-onset Alzheimer's disease.
    Hamuro A
    Aust N Z J Psychiatry; 2013 Jun; 47(6):583. PubMed ID: 23093052
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical aspects of cholinergic pharmacology.
    Hanin I
    Prog Brain Res; 1993; 98():421-2. PubMed ID: 8248530
    [No Abstract]   [Full Text] [Related]  

  • 28. The potential for muscarinic receptor subtype-specific pharmacotherapy for Alzheimer's disease.
    McKinney M; Coyle JT
    Mayo Clin Proc; 1991 Dec; 66(12):1225-37. PubMed ID: 1749291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Alzheimer's disease: irreparable damage in the brain?].
    Fessler B
    Med Monatsschr Pharm; 1993 Nov; 16(11):334-5. PubMed ID: 8272002
    [No Abstract]   [Full Text] [Related]  

  • 30. Are drugs targeted at Alzheimer's disease useful? 2. Insufficient evidence of worthwhile benefit.
    Byrne EJ; Arie T
    BMJ; 1990 Apr; 300(6732):1132-3; discussion 1131. PubMed ID: 2160850
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical drug trials in Alzheimer's disease.
    Crook T
    Ann N Y Acad Sci; 1985; 444():428-36. PubMed ID: 3893271
    [No Abstract]   [Full Text] [Related]  

  • 32. Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment.
    Francis PT; Palmer AM; Sims NR; Bowen DM; Davison AN; Esiri MM; Neary D; Snowden JS; Wilcock GK
    N Engl J Med; 1985 Jul; 313(1):7-11. PubMed ID: 2582256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholinergic controversies.
    Sarter M; Bruno JP; Dudchenko P
    Trends Neurosci; 1991 Nov; 14(11):484; author reply 485-6. PubMed ID: 1726764
    [No Abstract]   [Full Text] [Related]  

  • 34. [Alzheimer's disease].
    Derouesné C
    Presse Med; 1992 Jan 4-11; 21(1):13-5. PubMed ID: 1531257
    [No Abstract]   [Full Text] [Related]  

  • 35. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations.
    Sunderland T; Tariot PN; Newhouse PA
    Brain Res; 1988 Dec; 472(4):371-89. PubMed ID: 3066441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CNS distribution of cholinergic receptors--some questions from a clinical neuroscientist.
    Aquilonius SM
    Prog Brain Res; 1993; 98():73-5. PubMed ID: 8248539
    [No Abstract]   [Full Text] [Related]  

  • 37. [Galantamine: a novel cholinergic agent for Alzheimer's disease].
    Olazarán J; García G
    Neurologia; 2002 Oct; 17(8):429-36. PubMed ID: 12396973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cholinergic hypothesis: a historical overview, current perspective, and future directions.
    Bartus RT; Dean RL; Pontecorvo MJ; Flicker C
    Ann N Y Acad Sci; 1985; 444():332-58. PubMed ID: 2990293
    [No Abstract]   [Full Text] [Related]  

  • 39. [Cerebral glucose metabolism in presenile dementia of the Alzheimer type--follow-up of therapy with muscarinergic choline agonists].
    Szelies B; Herholz K; Pawlik G; Beil C; Wienhard K; Heiss WD
    Fortschr Neurol Psychiatr; 1986 Nov; 54(11):364-73. PubMed ID: 3492415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic frontiers in Alzheimer's disease.
    Miller SW; Mahoney JM; Jann MW
    Pharmacotherapy; 1992; 12(3):217-31. PubMed ID: 1608856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.